v3.26.1
Stock-based Payments (Tables)
 12 Months Ended
Apr. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation of Share Based Compensation Expense Stock-based compensation costs were recorded as follows (in thousands):
 Year Ended April 30,
 20262025
General and administrative$969 $414 
Sales and marketing78 125 
Research and development134 10 
TOS cost of sales56 105 
Total stock-based compensation expense$1,237 $654 
Schedule of Valuation Assumptions for Stock Options
Black-Scholes and Monte Carlo assumptions used to calculate the fair value of Champions options granted by the Company during the years ended April 30, 2026 and 2025 were as follows:
 Year Ended April 30,
20262025
Expected term in years
6
 6
Risk-free interest rates
3.6% - 4.5%
3.6% - 4.5%
Volatility
53% - 62%
54% - 63%
Dividend yield—%—%
Black-Scholes assumptions used to calculate the fair value of Corellia options granted by Corellia during May 2025 were as follows:

Year Ended April 30,
 20262025
Expected term in years60
Risk-free interest rates4.15%—%
Volatility65%—%
Dividend yield—%—%
Schedule of Stock Option Activity
The Company’s stock options activity and related information as of and for the years ended April 30, 2026 and 2025 is as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, May 1, 20251,671,182 7,500 1,678,682 $4.98 4.9$4,434,000 
Granted1,205,272 — 1,205,272 $7.08 9.3$— 
Exercised(109,656)— (109,656)$2.13   
Canceled(14,875)— (14,875)$7.23   
Forfeited(66,270)— (66,270)$7.53   
Expired(53,333)— (53,333)$11.96   
Outstanding, April 30, 2026
2,632,320 7,500 2,639,820 $5.84 6.4$2,673,000 
Vested and expected to vest as of April 30, 2026
2,632,320 7,500 2,639,820 $5.84 6.4$2,673,000 
Exercisable as of April 30, 2026
1,462,450 7,500 1,469,950 $4.86 4.0$2,618,000 
The stock options activity for the Corellia 2023 Global equity incentive plan for the year ended April 30, 2026 was as follows:
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 2025— — — $— — $— 
Granted300 — 300 $1,682.00 9.06$110,000 
Outstanding, April 30, 2026300 — 300 $1,682.00 9.06$110,000 
Vested and expected to vest as of April 30, 2026300 — 300 $1,682.00 9.06$110,000 
Exercisable as of April 30, 2026— — — $— — $—